*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Suzhou Basecare Medical Corporation Limited
# 蘇州貝康醫療股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2170)**

## INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board of Suzhou Basecare Medical Corporation Limited hereby announces the unaudited consolidated interim results of the Company and its subsidiaries (together, the "**Group**") for the six months ended June 30, 2025, together with the comparative figures for the corresponding period in 2024.

## FINANCIAL SUMMARY

| | **Six months ended June 30,** | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| | **(Unaudited)** | (Unaudited) |
| **Revenue** | **101,338** | 124,739 |
| Cost of sales | **(48,147)** | (66,861) |
| Gross profit | **53,191** | 57,878 |
| Loss from operations | **(115,846)** | (117,643) |
| Loss before taxation | **(123,023)** | (121,327) |
| Loss for the period | **(121,493)** | (119,915) |

| | **As of** | |
|---|---|---|
| | **June 30, 2025** | December 31, 2024 |
| | ***RMB'000*** | *RMB'000* |
| | **(Unaudited)** | (Audited) |
| **Financial Positions** | | |
| Non-current assets | **702,030** | 690,039 |
| Current assets | **864,995** | 979,242 |
| Non-current liabilities | **336,862** | 332,782 |
| Current liabilities | **198,487** | 194,684 |
| Net assets | **1,031,676** | 1,141,815 |
| Total equity attributable to equity shareholders of the Company | **1,032,946** | 1,143,066 |
| Non-controlling interests | **(1,270)** | (1,251) |

# MANAGEMENT DISCUSSION AND ANALYSIS

## Overview

We are an innovative medical device provider for assisted reproduction in the PRC, and we are committed to facilitating medical institutions and patients to access automatic, standard and intelligent assisted reproduction products, as well as stable and high-quality reproductive technologies. Our products are developed based on continuous innovation and clinical feedback, resulting in industry-leading clinical results and advancing reproduction science together with clinical studies. Our mission is to help more families to have healthy children. Our vision is to become the world's leading medical technology company.

Driven by our continuous innovative efforts, we have gradually built a full industry chain solution covering genetic testing, andrology diagnosis, cryopreservation, embryo culture and intelligent management.

In terms of genetic testing, our PGT-A test kit has obtained the first Class III medical device registration certificate (Guo Xie Zhu Zhun 20203400181) in China under the "National Special Approval for Innovative Medical Devices (國家創新醫療器械特別審批)", and we continue to promote the expansion of the PGT field to help achieve more comprehensive prenatal and postnatal care solutions in clinical practice.

In the field of andrology diagnosis, we have launched the intelligent sperm quality analyzer (BKA-210), which can complete non-destructive and accurate live sperm quality analysis within three minutes and significantly improve detection efficiency through AI algorithms; and the self sperm testing device (BKP200) expands professional-level testing to home scenarios, promoting universal application.

In terms of frozen storage, our intelligent liquid nitrogen tank (BCT38) is the first product in China that has been approved by NMPA and obtained the CE certificate, enabling real-time monitoring and safety management of sample storage; and the cryopreservation system (SG800) launched at the same time has a single-machine capacity of up to 30,000 to 50,000 tubes and supports docking with medical record systems to achieve zero-error, intelligent sample preservation.

In terms of embryo culture, we obtained the internationally leading Geri® Time-Lapse Incubator and Gems® embryo culture medium by acquiring BMX, and obtained the Class II medical device registration certificate for the Geri® Time-Lapse Incubator (Su Xie Zhu Zhun 20252181382) from Jiangsu MPA in July 2025, marking the successful transition from import to domestic production for this high-profile embryo culture equipment. Studies have shown that such culture system can significantly improve embryo quality and pregnancy success rate. At the same time, we have further optimized it after localization to significantly improve its clinical accessibility.

We also attach great importance to the application of AI in assisted reproductive clinical practice and have launched the iARMS intelligent management system, which connects hardware equipment such as genetic laboratories, andrology, cryopreservation and embryo culture to a unified platform. Through AI and Internet of Things technologies, we achieve medical record structuring, intelligent scheduling, real-time quality control and decision-making assistance, helping reproductive centers complete digital upgrades.

In the overseas market, the Company has established a sales and service network covering multiple countries and regions. We have obtained certifications from multiple authorities such as FDA, CE, and TGA for our products. We have also cooperated with many leading international reproductive institutions and scientific research centers to promote the implementation of intelligent IVF clinics and scientific research projects. Such initiatives have not only enhanced the Company's brand influence, but have also laid the foundation for the global promotion of domestically produced products.

Relying on the three major strategies of "full industry chain platform + international brand influence + AI intelligent upgrade", we have not only consolidated our technological and brand leadership in the Chinese market, but are also promoting China's independently innovative solutions to the world, contributing to the realization of eugenics and national population strategic goals.

Our full industry chain solutions are built based on five major laboratory scenarios: genetic laboratory ("**Live Browser**"), andrology laboratory ("**Live Morphology**"), embryo laboratory ("**Live View**"), cryopreservation laboratory ("**Live Storage**") and software laboratory ("**Live Intelligence**"). Specifically:

***1. Genetic Laboratory ("Live Browser")***

The genetic laboratory is dedicated to conducting embryonic molecular genetic testing, which is equipped with high-throughput gene sequencers, automated workstations, PCR analyzers, PGT kits and other equipment and consumables. In the genetic laboratory, experts through "Live Browser" can view and analyze genetic testing data while dynamically browsing and filtering data to better understand and analyze specific regions or variants in the genome.

PGT testing can help patients screen chromosomally normal embryos for transfer. According to the data of large-scale clinical trials, PGT-A kits can increase the clinical pregnancy rate to 72% and reduce the miscarriage rate to 6.9%. In addition, PGT-M kits and PGT-SR kits can block the transmission of genetic diseases to the next generation, giving birth to healthy children and safeguarding the quality of the Chinese population.

In September 2023, we obtained the national Class III medical device registration certificate for our localized high-throughput gene sequencer, DA500. In September 2024, we obtained the Class III medical device registration certificate for our DA5000 high-throughput gene sequencer, a latest domestic high-throughput gene sequencing platform, from NMPA (Guo Xie Zhu Zhun 20243221930).

In February 2020, we obtained our first Class III medical device registration certificate for our self-developed PGT-A kit, one of the medical devices of "National Special Approval for Innovative Medical Devices (國家創新醫療器械特別審批)" (Guo Xie Zhu Zhun 20203400181), and we obtained the approval from NMPA for the renewal of the certificate for a period of five years until February 20, 2030 in October 2024, which filled the clinical gap of the third generation IVF genetic testing kit in China. We also participated in the drafting of the industrial guidelines for the technical evaluation of quality control of PGT-A detection reagents, pioneering the commercialization of third generation IVF products.

***2. Andrology Laboratory ("Live Morphology")***

The andrology laboratory, being an indispensable part of reproduction center, focuses on the detection and evaluation of sperms. It evaluates male fertility indicators, including sperm concentration, vitality, morphology, and DNA fragments. According to the Frost & Sullivan's report, the sperm count of Chinese men has decreased by 75% over the past 40 years, and the infertility caused by male factors has been close to 40%. In China, the current practice of sperm test is mainly based on Computer Assisted Sperm Analysis (CASA), and sperms are counted through slide plates, which lacks reliability, repeatability and the ability to assess sperm morphology. To address these problems, our newly-developed intelligent sperm quality analyzer has broken through the technical limitations through the innovation of hardware technology such as microfluidics enabled by Live Morphology and microscopic imaging, as well as the AI big data model trained on more than 500,000 sperm data, which has realized the accurate detection of live sperm concentration, motility and morphology ("**Live Morphology**") for the first time globally, winning the outstanding award of the Disruptive Technology Innovation Competition (顛覆性技術創新大賽優秀項目) sponsored by the National Health Commission.

### *3. Embryology Laboratory ("Live View")*

The embryology laboratory is the most core laboratory for the growth and development of embryos in vitro, equipped with incubators, culture media, petri dishes and other equipment and consumables. The equipment and environment of the laboratory directly affect the survival rate of embryos. The equipment and consumables in the embryology laboratory require long R&D cycles and have high technical barriers. Our time-lapse incubator has six independent chambers, each equipped with independent heating, humidity supply, air supply devices and high-definition microscope camera system, which allows for stable cultivation and real-time monitoring of embryos without opening the lid and waiting. Users can observe the growth status of each embryo in real time ("**Live View**") to ensure that the embryos achieve the ideal conditions for growth.

### *4. Cryopreservation Laboratory ("Live Storage")*

The cryopreservation laboratory is the fertility preservation center for gametes and embryos, and houses equipment and consumables such as ultra-low temperature storage instruments, liquid nitrogen tanks, transfer tanks, and cryopreservation tubes. According to the Measures for the Administration of Human Assisted Reproduction (《人類輔助生殖管理辦法》), cryopreserved embryos must be stored for at least five years. It is anticipated that there will be ten million new embryos to be cryopreserved in China each year, indicating extremely high market demand.

Currently, reproduction centers need to manually select tubes and record voluminous embryo information. The absence of an information system hampers timely coordination and management, leading to potential mismatches in embryo information and resulting in medical accidents due to misimplantation of test tube babies. With the concept of real-time fertility preservation and location tracking ("**Live Storage**"), we developed the intelligent liquid nitrogen tank, which was the first certified ultra-low temperature storage product in China. We also developed the first automated ultra-low temperature embryo intelligent storage equipment that can store 30,000 to 50,000 gametes. Based on the idea of prompt positioning fertility storage, we layout in the fertility preservation market in China and globally, and provide leading hardware equipment for the fertility preservation industry.

### *5. Software Laboratory ("Live Intelligence")*

We build intelligent system for reproduction centers based on the concept of real-time data interconnection in the software laboratory ("**Live Intelligence**"). Our iARMS (Intelligent Assisted Reproduction Management System) provides a new generation of "AI + Internet of Things (IoT)" information solutions for the assisted reproduction sector based on the clinical pathway of reproduction, which establishes a multi-dimensional assisted reproduction electronic medical record system that runs through the reproduction cycle and covers patient medical records, medical diagnosis, treatment plans and etc. This system combines the genetic data of our genetic laboratory, the sperm test results of the andrology laboratory, the real-time growth monitoring of embryos in the embryology laboratory, and the sample information of the cryopreservation laboratory to realize the interconnection of data from various laboratories, create intelligent work environment for reproductive centers, improve the work efficiency of reproductive centers, to improve the safety of operations, ultimately improving the success rate of pregnancy.

Leveraging the rapid development of AI, iARMS integrates reproduction clinical information system with the concept of clinical auxiliary decision-making, thereby speeding up patient registration, examination, diagnosis and treatment, and breaking the isolated data islands in traditional information system. iARMs ensures the modularization and interconnection of the laboratories, and installs the IoT sample verification system to ensure the information security of each sample. Each module of iARMS is developed independently, allowing for easy upgrade and maintenance. iARMS will significantly improve the operating efficiency and satisfaction of the reproduction centers, serving as the development vision of the reproduction centers for the next two decades.

Currently, our commercialization is in a stable and steady growing stage. The model of independent R&D and mergers and acquisitions has enabled us to accumulate a wide range of customers in China and the global market. With the penetration of our brand and the launches of our new products, we will be able to commercialize various advantageous products through our existing channels and teams, unleash our growth potential in China and the global market, and enable us to rapidly establish a dominant position in market share.

The following diagram sets forth key details of our product portfolio as of the date of this announcement:



| Product | Stage of Reproductive Cycle | Approved /Planned Indications | Coverage | Research & Development Stage | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | | Preclinical Studies | | Registration Testing*** | Clinical Evaluation/Trial**** | Gain Access |
| | | | | Design and Development* | Function Validation and Verification** | | | |
| **Embryo Laboratory (Live View)** | | | | | | | | |
| Geri® Incubator | Pre-implantation | Embryo Sample | NMPA (imported) | Obtained Class II medical device registration certificate in November 2020 | | | | |
| | | | NMPA (domestical) | Obtained Class II medical device registration certificate in July 2025 | | | | |
| | | | CE | Obtained CE Marking in 2015 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2018 | | | | |
| | | | ANVISA (Brazil) | Obtained market authorization in 2023 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2015 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| | | | MFDA (South Korea) | Obtained market authorization in 2019 | | | | |
| Gavi® Instrument | Pre-implantation | Gamete and Embryo | CE | Obtained CE Marking in 2015 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Fertilisation Medium | Pre-implantation | Gamete Culturing | NMPA | Expected to obtain Class III registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Oocyte Retrieval Buffer | Pre-implantation | Oocyte Washing | NMPA | Expected to obtain Class III registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | HC (Canada) | Obtained market authorization in 2018 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Sperm Buffer | Pre-implantation | Sperm Processing | NMPA | Expected to obtain Class III registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | HC (Canada) | Obtained market authorization in 2016 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Vitbase | Pre-implantation | Gamete and Embryo | NMPA | ObtainedClass III registration certificate in August 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Vitrification Set Gems® Warming Set | Pre-implantation | Gamete and Embryo | NMPA | Expected to obtain Class III registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Gems® Cleavage Medium Gems® Blastocyst Medium Gems® Embroy Medium | Pre-implantation | Embryo Culturing | NMPA | Expected to obtain Class III registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2016 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2023 | | | | |
| | | | HC (Canada) | Obtained market authorization in 2016 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| Geri® Dish | Pre-implantation | Embryo Culturing | NMPA (imported) | Class II medical device registration certificate obtained in September 2023 | | | | |
| | | | NMPA (domestical) | Expected to obtain Class II registration certificate in 2025 | | | | |
| | | | CE | Obtained CE Marking in 2015 | | | | |
| | | | FDA | Obtained FDA certification in 2017 | | | | |
| | | | TGA (Australia) | Obtained market authorization in 2018 | | | | |
| | | | ANVISA (Brazil) | Obtained market authorization in 2018 | | | | |
| | | | MHRA (UK) | Obtained market authorization in 2016 | | | | |
| | | | TFDA (Thailand) | Obtained market authorization in 2022 | | | | |
| **Software Laboratory** | | | | | | | | |
| Intelligent assisted reproduction management system (iARMS) | Full-cycle | Universal | Commercial | Comprehensive commercialization commenced in 2023 | | | | |
| PGT-A Software | Pre-implantation | Aneuploidy | NMPA | Obtained Class II medical device registration certificate in June 2022 | | | | |
| PGT-M Software | Pre-implantation | Monogenic defects | NMPA | Expected to obtain registration certificate in 2026 | | | | |
| PGT-SR Software | Pre-implantation | Chromosome Structural Rearrangement | NMPA | Expected to obtain registration certificate in 2026 | | | | |
| Gidget@ Management System | Pre-implantation | Universal | Commercial | Comprehensive commercialization commenced in 2021 | | | | |

*Notes:*

* Includes principal raw material selection, manufacturing process validation and reaction system development

** Includes analytical performance evaluations and stability study

*** Refers to tests conducted by NMPA-recognized institutions to evaluate the performance of a medical device candidate. Passing the tests is a prerequisite to commencing the clinical trial

**** Unlike drugs, only one clinical trial is required for a medical device candidate, without phasing

1. For women undergoing IVF treatment who are 35 years old or older, couples who have experienced three or more IVF failures, couples who have experienced three or more spontaneous miscarriages or abnormal pregnancies, couples who have previously given birth to a child with chromosomal abnormalities or couples with chromosomal numerical alternations.

2. For carriers of thalassemia.

3. For carriers of chromosomal reciprocal translocation, robertsonian translocation or inversion.

## Business review

### *Products Portfolio and Product Candidates Pipeline*

As assisted reproductive technology is undergoing rapid development and iteration, with the aim of creating automatic, standard and intelligent assisted reproduction medical devices, we provide medical institutions with high-quality medical devices that meet clinical requirements, so as to improve both the success rate of assisted reproduction and work efficiency.

- *PGT-A kit*

  Our PGT-A kit is designed to detect aneuploidy, i.e., an abnormal number of chromosomes, in pre-implantation embryos created in the IVF process. Aneuploidy is a chromosomal disorder frequently associated with implantation failure. By identifying and choosing to avoid aneuploid embryos, clinicians can effectively increase chances for a successful pregnancy. Our product is the only NMPA-approved product for aneuploidy in China, with comprehensive chromosome screening (CCS) capabilities, as compared with conventional technologies, which can only screen a portion of chromosomes at a time. We have developed a proprietary strand displacement whole genome amplification (SDWGA) technology to lower amplification bias, a major clinical challenge, enabling our PGT-A kit to demonstrate 100% sensitivity and specificity in its registration clinical trial. With the help of our PGT-A kit, pregnancy and miscarriage rates from our clinical trial were 72.0% and 6.9%, respectively. By reference, pregnancy and miscarriage rates in IVF without aneuploidy screening were 45.0% and 32.0%, respectively, according to various unrelated studies (Schoolcraft et al. 2010; Wang et al. 2010). Further, due to our technological superiority, our PGT-A kit can generate results within one day, shortening the results turnaround time from the two weeks required by conventional technologies.

- *PGT-M kit*

  Our PGT-M kit is a key project of the 14th Five-Year Plan for National Key Research and Development Program of China (十四五國家重點研發計劃重點專項), which is designed to detect single-gene, or monogenic, defects in pre-implantation embryos, with the potential to cover common genetic-related disorders, including thalassemia, deafness and hereditary cancers. By identifying and choosing to avoid embryos with certain monogenic defects, clinicians can not only help to reduce chances for the baby to be born with or develop the relevant hereditary diseases, but also effectively stop the traits from being passed down to future generations in the patient family, which can be highly significant and encouraging for the patient.

A major challenge in PGT-M is the ability to accurately flag disease-causing genetic mutations with a limited amount of DNA samples. Conventional methods require pre-exam validation to analyze the DNA of parents or other family members in order to select suitable single nucleotide polymorphisms (SNPs), for different genetic disorders, before patient embryos can be tested. The SNPs selected may fail pre-exam validation, requiring re-selection and re-testing that take as long as two to three months and making standardized, mass clinical application difficult.

We have developed a PGT-M kit that leverages highly informative SNPs that we have identified through extensive studies and adopts a cutting-edge multiplex PCR sequencing library by capture, or MSLCap, a technology that allows comprehensively detection of the relevant SNPs in one test with improved sensitivity and specificity. Leveraging this technology, our PGT-M kit eliminates the need for patient-specific pre-exam validation, offering a standardized solution with mass clinical appeal that significantly shortens results turnaround time from approximately two months to less than two weeks and reducing testing costs for patients by about 60%. To date, our PGT-M kit is the first and only product of its kind that has completed NMPA registration testing in China. We completed clinical trials in March 2024, and expect to obtain registration approval from NMPA in 2025.

- *PGT-SR kit*

  Our PGT-SR kit is a key project of the 14th Five-Year Plan for National Key Research and Development Program of China (十四五國家重點研發計劃重點專項), and is designed to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. By identifying and choosing to avoid embryos with chromosomal structural re-arrangement, clinicians can, similar to the PGT-M scenario, not only help the patient avoid miscarriage and give birth successfully, but also stop this hereditary trait from running in the same family in future generations.

  However, there have been no effective clinical solutions for testing of this kind due to many kinds of potential structural rearrangements occurring on different chromosomes, which requires clinicians to design non-standardized, bespoke tests, making mass clinical application difficult. Our PGT-SR kit may become the first standardized commercial product of its kind in China with potential for mass clinical application, at affordable prices. Our PGT-SR kit adopts a proprietary ReTSeq technology that utilizes target capture technologies to focus on sequencing key genomic regions and conduct a haplotype linkage analysis to determine the parent-of-origin of a chromosome and detect carriers of chromosomal translocations.

Our PGT-SR kit has high mass market potential, offering one test with broad disease detectability and eliminating the need for patient specific pre-exam validation, which translates to faster result turnaround time, from several months to just two weeks, and significantly lowers the testing cost. In February 2021, our self-developed patent relating to the PGT-SR kit, a nucleic acid library preparation method and its application in the analysis of pre-implantation embryonic chromosomal structure abnormalities (一種核酸文庫構建方法及其在植入前胚胎染色體結構異常分析中的應用), was registered with China National Intellectual Property Administration (中國國家知識產權局). We completed the NMPA registration test in April 2023 and are currently undergoing clinical trials, and expect to obtain NMPA approval in 2026.

- *High-throughput gene sequencer (DA500 and DA5000)*

  The DA500 high-throughput gene sequencer is a domestic-developed compact and versatile desktop platform with single-slide gene sequencing that provides users with flexible and efficient sequencing options. The sequencer uses advanced biochemical and optical systems and supports two different chip specifications. It is capable of generating 10GB to 150GB sequencing data in a single operation. At the same time, it has the advantages of stable high-intensity signal and low sequencing error rate, which can meet the requirements of customers in terms of sequencing throughput and efficiency under various scenarios. Accompanying with our PGT analysis software, DA500 has realized automated data analysis and complete monitoring solution for gene testing. In September 2023, we obtained the Class III medical device registration certificate for the DA500 high-throughput gene sequencer from NMPA (Guo Xie Zhu Zhun 20233221281) and realized full commercialization.

  The DA5000 high-throughput gene sequencer, as a latest domestic high-throughput gene sequencing platform, is a key project of the 14th Five-Year Plan for National Key Research and Development Program of China (十四五國家重點研發計劃重點專項). The DA5000 high-throughput gene sequencer can provide one-stop genetic laboratory solution for assisted reproductive centers and has strong multi-sample and multi-project parallel processing capabilities. Compared to DA500 high-throughput gene sequencer, DA5000 high-throughput gene sequencer is capable of processing 40–50 embryo samples in a single test, with a throughput increase of more than 4 times. In September 2024, we obtained the Class III medical device registration certificate for the DA5000 high-throughput gene sequencer from NMPA (Guo Xie Zhu Zhun 20243221930).

- *Automated sample preparation system (BS1000C)*

  The BS1000C high-throughput automated sample preparation system is a high-throughput, feature-rich, and flexible desktop multi-function automated workstation that can automate most of the sample preparation process. This workstation is equipped with a 96-channel pipette, a built-in conventional high-throughput sequencing sample preparation process and a nucleic acid extraction process, as well as a fully automated operation design, so that it can achieve long-term unattended operation. Additionally, it can be customized according to customers' requirements, turning out to be an efficient and flexible automated sample preparation system for a wide range of applications.

- *PGT-A, PGT-M and PGT-SR analysis software*

  For the three PGT kits (PGT-A, PGT-M and PGT-SR), we have designed or are designing analysis software associated with sequencers and kits. We obtained the registration certificate for our PGT-A analysis software from NMPA in 2022, and we expected to obtain the registration certificates for our PGT-M analysis software and PGT-SR analysis software in 2025 and 2026, respectively. In the field of PGT, we have achieved a closed-loop marketing, covering kits, high-throughput sequencers and supporting software.

- *Time-lapse incubator (Geri®)*

  The core concept of our Geri® Time-Lapse Incubator is to provide safe and stable culture conditions for embryo culturing. The incubator includes six independent culturing chambers, and every chamber is exclusive for one patient, with independent air supply, humidity supply and heating, which is conducive to stability of embryo growth. Meanwhile, it is the world's first wet type time-lapse incubator, and can offer stable osmotic pressure environment for the development of embryos.

  Each chamber is equipped with a five-million-pixel high-definition camera component to capture images in 11 focal planes every five minutes, providing more dynamic developmental data for clinical decision-making. Each chamber is also independently equipped with a temperature sensor, a $CO^2$ sensor and a humidity warning system to monitor inside culturing environment in real time, and can generate real-time warnings for abnormal situations.

  Accompanying with intelligent analysis software, the incubator can automatically identify abnormal developmental patterns directly related to embryo implantation potential, helping embryologists select embryos with higher developmental potential and improving the utilization rate of embryos for patients. Upon the BMX acquisition, the Geri® Time-Lapse Incubator was incorporated into our product portfolio, and

we secured the relevant registration certificates from the NMPA (Guo Xie Zhu Jin 20202180490), CE, FDA, and TGA. In July 2025, we obtained the Class II medical device registration certificate for the Geri® Time-Lapse Incubator (Su Xie Zhu Zhun 20252181382) from Jiangsu MPA, marking the successful transition from import to domestic production for this high-profile embryo culture equipment. This domestic production enables significant cost reductions of over 30% through lower labor and supply chain expenses, which will further facilitate the expansion of Geri® Time-Lapse Incubator's sales in the Chinese market. Meanwhile, the overseas sales of the Geri® Time-Lapse Incubator continue to be maintained through BMX's existing production facilities and marketing channels.

- *Culture media (Gems)*

  Gems' full collection of culture media contains key ingredients that support embryo development and maintain stable cultivating environment (especially maintaining stable osmolality and pH value). The collection includes egg retrieval solution specified for gametes process, sperm gradient centrifugation solutions, sperm culture solutions, and sperm buffer solutions, vitrified solution specified for vitrification, thawing solution and Gavi solution, IVF medium for embryo cultivation, IVM medium, blastocyst medium and full process solution. All of Gems' products contain gentamicin for preventing microorganism contamination and sodium bicarbonate buffer. Saved for egg retrieval solution, all products contain human serum albumin (HSA).

  Since its clinical use in 2013, Gems has entered the market successfully through massive clinical data validation. Up to now, there have been more than ten thousand of babies born globally with the help of Gems. Gems' full collection of culture media products have been on the market for nine years and registered and certified as medical devices by CE, FDA and TGA, and has occupied certain market shares in China through original equipment manufacture (OEM) production and sales by other internationally renowned companies. We expected to complete registration and obtain approval of Gem as our own brand from NMPA in 2025.

- *Liquid nitrogen storage dewar (BCT38)*

  BCT38 liquid nitrogen storage dewar is our liquid nitrogen storage dewar with a digital management system, which was developed based on the conventional liquid nitrogen tank. BCT38 liquid nitrogen storage dewar is the first liquid nitrogen storage dewar product of the world to obtain the medical device registration certificate. It solved problems such as the frequent measurement of liquid gas level for embryo management, difficulty in permission management, and lack of operation logbook, etc. The device features real-time monitoring of tank temperature and alarm system, a double-verification lock, with permission level management, and an automatic

operation logbook, ensuring the safety of embryo preservation and the scientificity of experiment management. We obtained the Class II medical device registration certificate for liquid nitrogen storage dewar (BCT38) (Su Xie Zhu Zhun 20222221946) from Jiangsu MPA in November 2022.

- *Cryopreservation system (BSG800A and BSG800C)*

  Our self-developed cryopreservation system (BSG800A and BSG800C) is the first innovative device with full-automatic ultra-low temperature storage designed for the field of biological sample storage, which solves problems such as a heavy workload in storage management, space occupied by the storage of liquid nitrogen tanks, and a lack of information-based management. This device achieved automation of embryo storage and liquid nitrogen supply, an intelligence of information entry and retrieval, as well as ultra-low temperature protection throughout the process of sample transfer and storage, which significantly enhances work efficiency, and ensures the safety of long-term biological sample storage at the same time. We have received CE certificate for our cryopreservation system (BSG800A and BSG800C) in 2020, and obtained the Class II medical device registration certificate for this device (Su Xie Zhu Zhun 20242221830) from Jiangsu MPA in September 2024.

- *Sperm quality analyzer (BKA210)*

  The prevailing sperm quality testing method for clinical use can only analyze the concentration and motility of active sperms. As morphology analysis relies on inactive sperms with stain and requires manual cell counting under microscope, it has disadvantages such as complex manual operations, long duration, test results subjectively influenced by human processes, and chances of distorting the sperm morphology during the staining process.

  Our self-developed sperm quality analyzer (BKA210) is the world's first analytical device for unstained active sperms, which performs both static and dynamic analyses by AI of the concentration, motility and morphology for unstained sperms, and maintains the original morphology of sperm in analysis at the same time. It also avoids the change of sperm morphology during the staining process, resulting to an efficient, fast and objective analysis. In October 2023, we completed the registration inspection carried out by NMPA and obtained the Class II medical device registration certificate for sperm quality analyzer (BKA210) from Jiangsu MPA (Su Xie Zhu Zhun 20242222101) in November 2024.

- *Self Sperm Testing Device (BKP200)*

  Our self-developed self sperm testing device (BKP200) is a consumer-oriented home-based live sperm detection device, specifically designed for male reproductive health. This device adheres to the sperm quality testing standards specified in the World Health Organization Laboratory Manual for the Examination and Processing of Human Semen (6th Edition). The device features a compact and convenient design, allowing users to quickly and accurately test sperm quality at home, effectively addressing privacy concerns related to clinical examinations. The device is equipped with a built-in camera, ensuring consistent image quality for each test and preventing fluctuations in test results due to differences in smartphone camera configurations. The core functionality of the device focuses on the detection and analysis of live sperm, completing data processing within 15 seconds and generating detailed reports on sperm concentration and motility, helping users scientifically assess their fertility.

  We obtained the Class II medical device registration certificate for the self sperm testing device (BKP200) from Jiangsu MPA (Su Xie Zhu Zhun 20252220581) in April 2025. In the future, the device will be available through both online platforms and offline physical pharmacies, marking the expansion of the Company's sales channels from professional medical institutions to general consumer applications.

- *Automated vitrification instrument (Gavi)*

  Gavi is the first automated vitrification instrument in the world to be utilized in the process of freezing embryos and eggs in the IVF automated vitrification. By using the Gavi automated vitrification instrument to perform standardized refrigerating operations, the recovery rate of embryos after refrigerating can be improved while standardizing the operating procedures. At the same time, Gavi can also reduce the learning cost of new laboratory personnel and improve the overall management efficiency of the laboratory. We have obtained CE certificate for Gavi and it has been on the market for nearly seven years.

- *Intelligent assisted reproduction management system (iARMS)*

  iARMS (Intelligent Assisted Reproduction Management System) is based on the reproductive clinical path and provides the new generation of "AI + Internet of Things" information solutions in the assisted reproduction field, thereby establishing a multi-dimensional assisted reproduction management system that runs through the reproductive cycle and covers patient medical records, medical diagnosis, and treatment plans, etc.

Leveraging the rapid development of AI, iARMS integrates reproduction clinical information system with the concept of clinical auxiliary decision-making, thereby speeding up patient registration, examination, diagnosis and treatment, and breaking the isolated data islands in traditional information system. iARMs ensures the modularization and interconnection of the laboratories, and installs the IoT sample verification system to ensure the information security of each sample. Each module of iARMS is developed independently, allowing for easy upgrade and maintenance. iARMS will significantly improve the operating efficiency and satisfaction of the reproduction centers, serving as the development vision of the reproduction centers for the next two decades.

**Manufacturing**

The Company has built a manufacturing network spanning three countries. The Group's headquarters base is located in Suzhou, China, covering an area of 70,000 sq.m. and consisting of four GMP standard production workshops: intelligent equipment production workshop, high-end instrument production workshop, IVF reagent production workshop and culture fluid production workshop. The production base covers an area of 33,000 sq.m. and is dedicated to the manufacturing of reagents, consumables and instruments, while the R&D center covers an area of 22,000 sq.m. and focuses on technology introduction and international transformation. After the base is put into use, it will achieve global-scale delivery and provide high-quality medical products and services in the field of assisted reproduction. Our production bases in Thailand and Australia have a production history of over 15 years and have facilitated us in achieving the milestone of delivering products to over 1,000 overseas customers, and the Time-Lapse Incubator (Geri®) and Culture media (Gems) produced at these bases are deeply trusted by the customers. All of our production bases have passed UDI full-chain traceability management, and have obtained more than 30 international certifications, including GMP certification and ISO13485 certification. This system featuring "intelligent manufacturing in China + global delivery (中國智造+全球交付)" supports the large-scale sales of our products.

**R&D**

During the Reporting Period, we maintained an active advancement in our R&D endeavors.

In April 2025, we obtained the Class II medical device registration certificate for the self sperm testing device from Jiangsu MPA (Su Xie Zhu Zhun 20252220581). The self-developed self sperm testing device is a consumer-oriented home-based live sperm detection device, featuring a compact and convenient design and allowing users to quickly and accurately test sperm quality at home, effectively addressing privacy concerns related to clinical examinations.

In July 2025, we obtained the Class II medical device registration certificate for the Geri® Time-Lapse Incubator (Su Xie Zhu Zhun 20252181382) from Jiangsu MPA, realizing the "transition from imports to domestic production", by which the cost can be reduced by more than 30%.

In August 2025, we obtained the Class III medical device registration certificate for the GEMS series embryo culture medium (VitBase embryo processing fluid) (Guo Xie Zhu Jin 20253180356) from NMPA, which is the first product among the 11 culture mediums among the GEMS series embryo culture mediums, which lays the foundation for the subsequent localization of the full range of embryo culture mediums in China.

**Intellectual Property**

As of June 30, 2025, we had registered 149 patents, 133 trademarks, 59 software copyrights and 16 domain names in China. We had also registered 9 trademarks in Hong Kong and 5 trademarks in Taiwan. As of the same date, we have submitted 67 patent applications in China.

**Commercialization**

At present, we have established three major overseas sales regions covering Europe-Middle East-Africa (EMEA), Asia Pacific (APAC) and North America, forming a strategic framework of "overall planning of China headquarters and efficient coordination of the regional centers (中國總部統籌全局、區域中心高效協同)". Relying on the deep accumulation and R&D advantages of the local market in our China headquarters, we continue to strengthen our overseas business by providing cutting-edge technology empowerment and strategic decision-making support. With the mature industrial ecology in the field of assisted reproduction of its global operation headquarters in Australia, BMX coordinates production collaboration, the output of technical standards and the training of high-end talent in the overseas market. As of June 30, 2025, we had a total of over 170 sales personnel around the world. During the Reporting Period, we collaborated with over 48 distributors in Mainland China (including the platform distributors such as ShangPharma Holding Company Limited (上藥控股有限公司) and Sinopharm Holding Company Limited (國藥控股股份有限公司)) and more than 40 other distributors around the world, serving more than 1,000 clinical institutions.

- ***One of our key strategies is to deeply explore and expand key customers:***

  In February 2025, we entered into a strategic cooperation agreement (the "**Strategic Cooperation Agreement**") with Rhea Labs Pte. Ltd ("**Rhea Labs**"), a wholly owned subsidiary of Rhea Fertility, pursuant to which Genea Biomedx was expected to provide Rhea Labs with high-quality medical products and comprehensive solutions, jointly promote brand building in particular regions, and collaborate on the development of new products based on AI with Rhea Labs. For further details on the Strategic Cooperation Agreement, please refer to the announcement of the Company dated February 25, 2025.

  In March 2025, certain senior executives from IVI RMA Global ("**IVI RMA**"), a leading global reproductive medical group, visited the Company's headquarters in Suzhou and held a three-day strategic meeting with the BMX's management team. Based on the long-term cooperation relationship in Geri® Time-Lapse Incubator and Gems® embryo culture medium, we will further expand the cooperation with IVI RMA into areas such as PGT equipment and reagents, andrology AI testing, automated ultra-low temperature storage and laboratory full-process management systems, forming a full-chain cooperation from research and development, transformation to clinical application. As the world's largest group with over 200,000 cycles, IVI RMA will provide important support for the clinical implementation and global promotion of the Company's technology.

- ***Developing overseas business is our unshakable strategic core, and it is also an important way to break through industry competition and define future standards.***

  In overseas markets, relying on a global channel network of more than 600 reproductive center customers, our core products are accelerating their penetration in an internationalized manner. PGT test kits (Genie), gene sequencers (Genie Sequencer), sperm quality analyzers (Glimmer Semen Analyser), liquid nitrogen storage dewar (Gelida 47), cryopreservation system (Gelida 800) and smart laboratory management systems (Guardian) have begun to fully penetrate high-end markets in Europe, the Middle East, Asia Pacific, the Americas, etc., and have simultaneously started international certifications such as CE and FDA to promote global compliance access of products.

## Important Events after the End of the Reporting Period

There are no important event occurred after the end of Reporting Period and up to the date of this announcement.

## Outlook and Strategies

To accomplish the Company's vision, we intend to implement the following business strategies: (i) to build an assisted reproductive platform covering the full-industrial chain, (ii) to expand business performance by leveraging brand value and international influence, and (iii) to leverage AI to enable an intelligent upgrade, jointly drive the Company's competitiveness and growth in domestic and overseas markets.

Through technological innovation, brand accumulation and intelligent upgrading, the Company will further expand the global market and achieve long-term sustainable development while improving China's independent and controllable level of reproductive health.

### *(i) To build an assisted reproductive platform covering the full-industrial chain*

The Company has built a full-industrial chain layout characterized by a "pyramid shape", making it one of the few companies in the world with full-industrial chain capabilities, enhancing China's independent control over core technologies and products and providing solid support for our international expansion.

- **High-end technical layer:** preimplantation genetic testing products represented by PGT-A are the first products of their kind approved in China, creating a first-mover advantage. The Company will continue to promote the expansion of the PGT field and help reproductive centers establish genetic laboratory systems, representing the highest technological barriers in the industry.

- **Core extension layer:** in terms of cryogenic storage, the Company launched China's first NMPA-registered and CE-certified intelligent liquid nitrogen tank, as well as the automated cryopreservation system (SG800) to meet rapidly growing clinical needs. By investing in Zhejiang Cellpro Biotech Co., Ltd. (浙江星博生物科技股份有限公司), we entered the field of andrology testing, integrating the advantages of flow cytometry, DNA fragmentation index (DFI) and male genetic testing to form a full-process screening of "sperm + embryo". The independently developed intelligent sperm quality analyzer (BKA-210) and self sperm testing device (BKP200) achieve "medical-grade + home-grade" coverage.

- **Basic support layer:** in the embryo culture segment, the Company acquired the world-leading Geri® Time-Lapse Incubator and Gems® embryo culture medium through the acquisition of Genea Biomedx, and achieved localization registration of Geri® Time-Lapse Incubator in 2025, marking a key breakthrough for China in the field of high-end equipment. We're also accelerating the localization process of the Gems® embryo culture medium, and will form a complete supporting system of "equipment + consumables" in the future.

- **Software ecosystem:** through the independently developed iARMS intelligent assisted reproductive management system, the Company has achieved full access to hardware equipment and cross-laboratory data, providing customers with a "smart reproductive center" solution covering the entire cycle.

***(ii) To expand business performance by leveraging brand value and international influence***

We have gradually established a brand image of "professional, innovative and international".

In the domestic market, the Company's products have been used by more than 70% of the leading reproductive centers, and through strategic cooperation with Shanghai Jinghua Medical Management Co., Ltd. (上海菁華醫療管理股份有限公司), Jiayin Hospital Group Co., Ltd. (佳音醫院集團股份有限公司), Jinxin Fertility Group Limited and others, the Company has created demonstration projects such as genetic laboratories and intelligent assisted reproductive centers, further enhancing its clinical recognition and industry influence. In the overseas market, the Company has established a sales and service network covering more than 20 countries and more than 600 reproductive centers through the acquisition of Genea Biomedx, and has reached strategic cooperation with global leading reproductive institutions such as Spain's IVIRMA and Singapore's Rhea Labs to jointly develop smart IVF clinics. Leveraging the international certifications of Geri® Time-Lapse Incubator and Gems® embryo culture medium, the Company has achieved breakthroughs in key customer models in the Europe, the Middle East and Africa (EMEA) and Asia-Pacific (APAC) regions, and accelerated channel expansion in emerging markets.

The enhancement of brand and international influence not only brings about an increase in product penetration and enhanced bargaining power, but also provides support for the Company to build long-term valuation logic in the capital market. In the future, the Company will continue to leverage the endorsement of international brands to accelerate the global promotion of domestically produced new products, and play a demonstration role in China to promote rapid penetration under the medical insurance and policy environment, and achieve dual-wheel driven growth.

***(iii) To leverage AI to enable an intelligent upgrade, jointly drive the Company's competitiveness and growth in domestic and overseas markets***

AI is becoming the core engine for our strategic upgrades. We propose "AI-led intelligent assisted reproduction" through a comprehensive layout in multiple laboratory scenarios such as genetics, andrology, embryos and cryopreservation. We use hardware equipment as the data entry point and the iARMS intelligent management system as the hub to connect scattered clinical data into a complete closed loop, which will eventually be accumulated into data assets to promote the intelligent upgrade of the industry.

In the genetics laboratory, the Company relies on gene sequencers and a full range of PGT kits to accumulate a large amount of genomic data, providing basic support for eugenics and good parenting; in the andrology laboratory, the intelligent sperm quality analyzer (BKA-210) and the self sperm testing device (BKP200) cover clinical and home scenarios respectively, pushing sperm testing into a new stage of AI and universal accessibility; in the cryopreservation laboratory, intelligent liquid nitrogen tanks and the automated cryopreservation system (BSG800) enable full-process digital sample management, ensuring "zero errors" in fertility preservation; and in the embryo laboratory, the Geri® Time-Lapse Incubator and Gems® embryo culture medium jointly construct an internationally leading interference-free culture system, and the accompanying EEVA® embryo assessment system, as the world's first FDA-certified AI analysis software, can increase the efficiency of high-quality embryo screening by approximately 40%, significantly improving clinical pregnancy rates and live birth rates.

The data generated by these scene devices is uniformly accessed and managed through the iARMS intelligent management system, realizing medical record structuring, intelligent scheduling, quality control management and AI-assisted decision-making, and promoting the upgrading of traditional reproductive centers to intelligent reproductive centers. As data accumulates, the Company is building an AI analysis matrix covering embryos, sperm and frozen samples, and exploring intelligent embryo transplantation plans and personalized interventions, gradually advancing AI from single-point assistance to full-process intelligent decision-making.

Relying on Genea Biomedx's global channels and cooperating with leading institutions such as IVI RMA and Rhea Labs, the Company is promoting the implementation of AI-driven intelligent solutions in markets such as Europe, Asia Pacific and North America, and gradually exploring data assetization and clinical standardization. The Company's vision is to become the world's first "AI+Reproduction" platform enterprise, redefine the technological boundaries of assisted reproduction through an AI-led intelligent reproductive ecosystem, and continue to contribute to China's reproductive health and global eugenics.

**Cautionary statement required under Rule 18A.08(3) of the Listing Rules: We cannot guarantee that we will ultimately develop or market our Core Product and other products in our product portfolio successfully.**

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS

*For the six months ended 30 June 2025 — unaudited*

| | | Six months ended 30 June | |
|---|---|---|---|
| | | **2025** | 2024 |
| | *Notes* | ***RMB'000*** | *RMB'000* |
| **Revenue** | *4* | **101,338** | 124,739 |
| Cost of sales | | **(48,147)** | (66,861) |
| **Gross profit** | | **53,191** | 57,878 |
| Other net income | *5* | **14,938** | 25,207 |
| Selling and distribution expenses | | **(52,862)** | (50,658) |
| Administrative expenses | | **(74,212)** | (80,380) |
| Research and development expenses | | **(56,812)** | (69,639) |
| Other operating expenses | | **(89)** | (51) |
| **Loss from operations** | | **(115,846)** | (117,643) |
| Finance costs | *6(a)* | **(7,177)** | (3,684) |
| **Loss before taxation** | *6* | **(123,023)** | (121,327) |
| Income tax | *7(a)* | **1,530** | 1,412 |
| **Loss for the period** | | **(121,493)** | (119,915) |
| **Attributable to:** | | | |
| Equity shareholders of the Company | | **(121,477)** | (119,912) |
| Non-controlling interests | | **(16)** | (3) |
| **Loss per share (RMB)** | *8* | | |
| Basic and diluted (RMB) | | **(0.4)** | (0.4) |

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

*For the six months ended 30 June 2025 — unaudited*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| **Loss for the period** | **(121,493)** | (119,915) |
| **Other comprehensive income for the period, net of nil tax** | | |
| Items that are or may be reclassified subsequently to profit or loss: | | |
| Exchange differences on translation of financial statements of overseas subsidiaries | **11,357** | (5,557) |
| **Other comprehensive income for the period** | **11,357** | (5,557) |
| **Total comprehensive income for the period** | **(110,136)** | (125,472) |
| **Attributable to:** | | |
| Equity shareholders of the Company | **(110,120)** | (125,469) |
| Non-controlling interests | **(16)** | (3) |
| **Total comprehensive income for the period** | **(110,136)** | (125,472) |

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

*At 30 June 2025 — unaudited*

| | Note | **As at 30 June 2025** ***RMB'000*** | As at 31 December 2024 *RMB'000* |
|---|---|---|---|
| **Non-current assets** | | | |
| Property, plant and equipment | *9* | **391,647** | 380,691 |
| Right-of-use assets | | **12,818** | 15,587 |
| Intangible assets | | **98,170** | 99,601 |
| Goodwill | | **142,902** | 137,570 |
| Financial assets measured at fair value through profit or loss ("**FVPL**") | *10* | **42,895** | 37,532 |
| Other non-current assets | | **13,234** | 18,710 |
| Deferred tax assets | *7(b)* | **364** | 348 |
| | | **702,030** | 690,039 |
| **Current assets** | | | |
| Inventories | | **124,152** | 92,404 |
| Trade and other receivables | *11* | **193,916** | 200,279 |
| Other current assets | | **2,634** | 564 |
| Time deposits | *12* | **—** | 111,884 |
| Restricted cash | *12* | **419** | 1,362 |
| Cash and cash equivalents | *12* | **543,874** | 572,749 |
| | | **864,995** | 979,242 |
| **Current liabilities** | | | |
| Trade and other payables | *13* | **160,515** | 163,881 |
| Contract liabilities | | **501** | 1,663 |
| Bank loans | *14* | **32,275** | 24,358 |
| Lease liabilities | | **4,812** | 4,408 |
| Income tax payable | | **384** | 374 |
| | | **198,487** | 194,684 |
| **Net current assets** | | **666,508** | 784,558 |
| **Total assets less current liabilities** | | **1,368,538** | 1,474,597 |

| | Note | As at 30 June 2025 RMB'000 | As at 31 December 2024 RMB'000 |
|---|---|---|---|
| **Non-current liabilities** | | | |
| Bank loans | *14* | **303,689** | 296,207 |
| Lease liabilities | | **1,454** | 3,447 |
| Deferred tax liabilities | *7(b)* | **29,435** | 29,863 |
| Other non-current liabilities | | **2,284** | 3,265 |
| | | **336,862** | 332,782 |
| **NET ASSETS** | | **1,031,676** | 1,141,815 |
| **CAPITAL AND RESERVES** | | | |
| Share capital | | **273,526** | 273,526 |
| Reserves | | **759,420** | 869,540 |
| **Total equity attributable to equity shareholders of the Company** | | **1,032,946** | 1,143,066 |
| **Non-controlling interests** | | **(1,270)** | (1,251) |
| **TOTAL EQUITY** | | **1,031,676** | 1,141,815 |

## Notes:

### 1 GENERAL INFORMATION

Suzhou Basecare Medical Corporation Limited (the "**Company**"), formerly known as Jiangsu Double Helix Biological Technology Co., Ltd., was established in Suzhou, Jiangsu Province, People's Republic of China (the "**PRC**") on 14 December 2010 as a limited liability company. Upon approval by the Company's board meeting held on 11 August 2020, the Company was converted from a limited liability company into a joint stock limited liability company and changed its registered name from Jiangsu Double Helix Biological Technology Co., Ltd. to Suzhou Basecare Medical Corporation Limited.

The Company and its subsidiaries (together, the "**Group**") are principally engaged in sales of genetic testing kits and sales of genetic testing devices, instruments and consumables.

The H shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 8 February 2021.

### 2 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard ("**IAS**") 34, *Interim financial reporting* as issued by the International Accounting Standards Board ("**IASB**"). It was authorised for issue on 29 August 2025.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2024 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards ("**IFRSs**").

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity* as issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The financial information relating to the financial year ended 31 December 2024 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year but is derived from those financial statements. Further information relating to these financial statements for the year ended 31 December 2024 are available from the Company's registered office. The auditors have expressed an unqualified opinion on these financial statements in their report dated 28 March 2025.

## 3 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to IAS 21, *The effects of changes in foreign exchange rates — Lack of exchangeability* as issued by the IASB to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

## 4 REVENUE AND SEGMENT REPORTING

During the period, the Group mainly derives revenue from the sales of testing kits and sales of testing devices, instruments and consumables.

### *(a) Disaggregation of revenue*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| **Revenue from contracts with customers within the scope of IFRS 15** | | |
| Disaggregated by major products of service lines | | |
| — Sales of testing kits | **54,783** | 56,559 |
| — Sales of testing devices, instruments and consumables | **36,090** | 59,539 |
| — Others | **10,465** | 8,641 |
| | **101,338** | 124,739 |
| Disaggregated by timing of revenue recognition | | |
| — Point in time | **92,852** | 118,532 |
| — Over time | **8,486** | 6,207 |
| | **101,338** | 124,739 |
| Disaggregated by geographical location of customers | | |
| — The PRC | **54,195** | 80,646 |
| — Europe | **27,482** | 26,782 |
| — Asia (excluding the PRC) | **9,725** | 10,880 |
| — Others | **9,936** | 6,431 |
| | **101,338** | 124,739 |

The above table sets out information about the geographical location of the Group's revenue from external customers. The geographical location of external customers is based on the location at which the goods are delivered or services are provided.

***(b) Information about major customers***

Revenue from major customers contributing over 10% of the Group's revenue are set out as below:

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Customer A | **N/A*** | 13,689 |

* *Less than 10% of the Group's revenue in the respective periods.*

***(c) Segment reporting***

Based on the manner in which information is reported internally, the Group's most senior executive management manages the Group's businesses and reviews the Group's operation by geographic areas, for the purposes of resource allocation and performance assessment. Specifically, the Group's reportable segments under IFRS 8 are as follows:

- The PRC
- Australia

Disaggregation of revenue from contracts with customers by timing of revenue recognition, as well as information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the period is set out below.

| | **The PRC** | | **Australia** | | **Total** | |
|---|---|---|---|---|---|---|
| | **2025** | 2024 | **2025** | 2024 | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* | ***RMB'000*** | *RMB'000* | ***RMB'000*** | *RMB'000* |
| For the six months ended 30 June 2025 | | | | | | |
| **Disaggregated by timing of revenue recognition** | | | | | | |
| Point in time | **52,407** | 80,646 | **40,445** | 37,886 | **92,852** | 118,532 |
| Over time | **1,788** | — | **6,698** | 6,207 | **8,486** | 6,207 |
| Revenue from external customers | **54,195** | 80,646 | **47,143** | 44,093 | **101,338** | 124,739 |
| Inter-segment revenue | **—** | — | **37,693** | 30,075 | **37,693** | 30,075 |
| Reportable segment revenue | **54,195** | 80,646 | **84,836** | 74,168 | **139,031** | 154,814 |
| Reportable segment loss before tax | **(115,742)** | (98,324) | **2,689** | (15,852) | **(113,053)** | (114,176) |
| As at 30 June 2025 | | | | | | |
| **Reportable segment assets** | **1,264,126** | 1,482,609 | **412,413** | 348,572 | **1,676,539** | 1,831,181 |
| **Reportable segment liabilities** | **440,479** | 443,988 | **181,999** | 105,016 | **622,478** | 549,004 |

*(d) Reconciliation of reportable segment profit or loss*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Total reportable segments' loss before taxation | **(113,053)** | (114,176) |
| Elimination of inter-segment transaction | **(8,235)** | (5,145) |
| Unallocated expenses | **(1,735)** | (2,006) |
| Consolidated loss before taxation | **(123,023)** | (121,327) |

## 5 OTHER NET INCOME

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Government grants (i) | **1,894** | 2,783 |
| Interest income from bank deposits | **6,819** | 15,338 |
| Net realised and unrealised gain on financial assets measured at FVPL | **3,107** | 1,009 |
| Net foreign exchange gain | **2,678** | 5,306 |
| Others | **440** | 771 |
| | **14,938** | 25,207 |

(i) Government grants primarily comprise subsidies received from the government for encouragement of research and development projects.

## 6 LOSS BEFORE TAXATION

### *(a) Finance costs*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Interest on bank loans | **6,939** | 5,623 |
| Interest on lease liabilities | **238** | 250 |
| Total finance costs on financial liabilities not at fair value through profit or loss | **7,177** | 5,873 |
| Less: borrowing costs capitalised into properties under construction | **—** | (2,189) |
| | **7,177** | 3,684 |

### *(b) Other items*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Depreciation of property, plant and equipment | **14,986** | 7,690 |
| Depreciation of right-of-use assets | **2,754** | 2,743 |
| Amortisation of intangible assets | **5,172** | 5,406 |
| Total amortisation and depreciation | **22,912** | 15,839 |
| Less: depreciation expense of land use rights capitalised into properties under construction | **—** | (91) |
| Amortisation and depreciation charged directly to profit or loss | **22,912** | 15,748 |
| Impairment losses on trade and other receivables | **12,112** | 13,514 |
| Research and development expenses (i) | **56,812** | 69,639 |

(i) During the six months ended 30 June 2025, research and development expenses include staff costs and depreciation and amortization expenses of RMB36,704,000 (six months ended 30 June 2024: RMB36,913,000), which amounts are also included in the respective total amounts disclosed separately above.

## 7 INCOME TAX AND DEFERRED TAX

### *(a) Taxation in the consolidated statement of profit or loss and other comprehensive income represents:*

| | Six months ended 30 June | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| Current tax — the PRC Corporate income tax ("**CIT**") | **—** | — |
| Current tax — other overseas countries | **24** | 42 |
| Deferred tax | **(1,554)** | (1,454) |
| Total | **(1,530)** | (1,412) |

*(i) Statutory tax rate*

Under the Corporate Income Tax Law of the PRC (the "**CIT Law**"), the PRC statutory income tax rate is 25% under the CIT Law. The Group's subsidiaries in the PRC are subject to PRC income tax rate at 25% unless otherwise specified.

Pursuant to the income tax rules and regulations of Australia, the Group's subsidiaries in Australia are subject to the Australian Income Tax at a rate of 30%. No provision for Australian Income Tax was made for the Group's subsidiaries in Australia, as these subsidiaries did not have assessable profits for Australia Income Tax for the six months ended 30 June 2025.

Taxation for other overseas subsidiaries is charged at the appropriate current rates of taxation ruling in the relevant countries.

*(ii) Preferential tax*

Under the CIT Law of the PRC and its relevant regulation, entities that qualified as high-technology enterprise are entitled to a preferential income tax rate of 15%. Suzhou Basecare Medical Device Co., Ltd. obtained its renewed certificate of high-technology enterprise on 6 November 2023 and is subject to income tax rate at 15% for a three-year period.

Under the CIT Law of the PRC and its relevant regulation, an additional 100% of qualified research and development expenses incurred would be allowed to be deducted from the taxable income for the year ending 31 December 2025.

### *(b) Deferred tax*

As at 30 June 2025, deferred tax assets of RMB364,000 mainly represent temporary differences arising from credit loss allowance and employee benefits and deferred tax liabilities of RMB29,435,000 arising from fair value adjustments in respect of net assets acquired in business combination in 2023.

## 8 LOSS PER SHARE

The calculation of basic loss per share for the six months ended 30 June 2025 is based on the loss attributable to equity shareholders of the Company of RMB121,477,000 (six months ended 30 June 2024: loss of RMB119,912,000) and the weighted average of 273,526,000 ordinary shares (six months ended 30 June 2024: 273,526,000 shares) in issue.

There were no potential dilutive ordinary shares for the period ended 30 June 2025 and 2024, and therefore dilutive loss per share are the same as the basic loss per share.

## 9 PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired equipment with a cost of RMB19,258,000 (six months ended 30 June 2024: RMB7,206,000) and capitalised construction in progress which primarily comprised production line of RMB5,318,000 (six months ended 30 June 2024: RMB15,493,000).

## 10 FINANCIAL ASSETS MEASURED AT FVPL

| | **As at 30 June 2025** | As at 31 December 2024 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Unlisted fund investment (i) | **11,274** | 5,533 |
| Unlisted equity investment (ii) | **20,784** | 20,592 |
| Derivative financial instrument (ii) | **10,837** | 11,407 |
| **Total** | **42,895** | 37,532 |

(i) On 10 August 2022, the Group entered into a subscription agreement with an independent third party pursuant to which the Group agreed to subscribe the limited partnership interest in TruMed Health Innovation Fund LP, a Cayman Islands exempted limited partnership (the "**Fund**") represented by a total commitment of USD1.50 million (equivalent to approximately RMB10,690,000). The Fund principally makes equity and equity-related investments in healthcare industry.

As at 30 June 2025, the Group has contributed USD1,151,000 (equivalent to approximately RMB8,244,000) (31 December 2024: USD776,000 (equivalent to approximately RMB5,578,000)) to the fund, representing 1.1% (31 December 2024: 1.1%) of the total size of the fund. For the six months ended 30 June 2025, the Group recognised the fair value changes of RMB3,048,000 in unrealised gain on financial assets measured at FVPL (six months ended 30 June 2024: RMB660,000).

(ii) The unlisted equity investment and the derivative financial instrument represent the Group's equity interests in Zhejiang Cellpro Biotech Corporation Limited ("**Cellpro Biotech**") and a put option granted by Cellpro Biotech and its original shareholders, which were recognised as financial assets measured at FVPL with the fair value change being recognised in unrealised gain or loss on financial assets measured at FVPL.

## 11 TRADE AND OTHER RECEIVABLES

As at the end of the reporting period, the ageing analysis of trade debtors receivable (which are included in trade and other receivables), based on the invoice date and net of loss allowance, was as follows:

| | **At 30 June 2025** | At 31 December 2024 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Within 6 months | **138,157** | 161,280 |
| 6–12 months | **25,945** | 5,363 |
| 12–18 months | **97** | 1,207 |
| Trade debtors receivable, net of loss allowance | **164,199** | 167,850 |
| Prepayments to suppliers | **21,696** | 22,117 |
| Deposits | **1,606** | 2,523 |
| Interest receivables | **2,422** | 2,746 |
| Others | **3,993** | 5,043 |
| | **193,916** | 200,279 |

Trade debtors are normally due within 60 to 360 days from the date of billing.

The Group's exposure to credit risk arising from trade receivables is influenced mainly by the individual characteristics of each customer. The default risk of the country in which the customers operate also has an influence on credit risk. Management has a credit policy in place and the exposure to these credit risks are monitored on an ongoing basis.

## 12 TIME DEPOSITS, CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

| | **As at 30 June 2025** | As at 31 December 2024 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Time deposits with original terms over 3 months | **—** | 111,884 |
| Cash at banks | **296,906** | 574,111 |
| Time deposits with original terms within 3 months | **247,387** | — |
| Less: Restricted cash | **(419)** | (1,362) |
| Cash and cash equivalents | **543,874** | 572,749 |

As at 30 June 2025 and 31 December 2024, cash and cash equivalents situated in Mainland China amounted to RMB351,060,000 and RMB413,714,000, respectively. Remittance of funds out of Mainland China is subject to relevant rules and regulations of foreign exchange control.

## 13 TRADE AND OTHER PAYABLES

As at the end of the reporting period, the ageing analysis of trade creditors (which are included in trade and other payables), based on the invoice date, is as follows:

| | **As at 30 June 2025** | As at 31 December 2024 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Within 3 months | **40,525** | 21,670 |
| 3–6 months | **10,527** | 2,431 |
| 6–9 months | **4,865** | 1,228 |
| 9–12 months | **95** | 157 |
| Over 1 year | **1,487** | 2,135 |
| Total trade payables | **57,499** | 27,621 |
| Payroll payables | **16,820** | 23,698 |
| Payables for marketing expenses | **13,394** | 12,633 |
| Interest payables | **406** | 456 |
| Payables for purchases of property, plant and equipment | **44,387** | 61,487 |
| Other payables and accruals | **28,009** | 37,986 |
| | **160,515** | 163,881 |

All of the trade and other payables are expected to be settled within one year.

## 14 BANK LOANS

| | As at 30 June 2025 *RMB'000* | As at 31 December 2024 *RMB'000* |
|---|---|---|
| **Current** | | |
| Current proportion of secured long-term bank loans | **19,275** | 13,000 |
| Current proportion of unsecured long-term bank loans | **13,000** | 11,358 |
| | **32,275** | 24,358 |
| **Non-current** | | |
| Secured long-term bank loans | **199,689** | 184,065 |
| Unsecured long-term bank loans | **104,000** | 112,142 |
| | **303,689** | 296,207 |

## 15 DIVIDENDS

No dividends were paid or declared by the Company or any of its subsidiaries of the Group during the reporting period (six months ended 30 June 2024: Nil).

## FINANCIAL REVIEW

### Revenue

During the Reporting Period, we generated revenue from sales of various types of testing kits, testing and cryopreservation devices and instruments, embryo culture devices and embryo culture solution, consumables and other products.

Our revenue decreased by 18.8% from RMB124.7 million for the six months ended June 30, 2024 to RMB101.3 million for the six months ended June 30, 2025. The decrease was due to the overall slowdown in industry growth, which affected the Group's performance, as well as the Group's proactive reduction of some relatively less profitable projects this year with the goal of improving overall profitability.

### Cost of Sales

Our cost of sales consists of (i) material costs, representing purchase costs of the distributed products and raw material cost for our self-developed products; (ii) staff costs; (iii) depreciation expenses, primarily including depreciation of property, plant and equipment and right-of-use assets; and (iv) others, primarily including utility fees, property rental expenses, logistics expenses and equipment maintenance expenses.

Our cost of sales decreased by 28.1% from RMB66.9 million for the six months ended June 30, 2024 to RMB48.1 million for the six months ended June 30, 2025, primarily due to the decrease in revenue.

### Gross Profit and Gross Profit Margin

As a result of the aforementioned factors, the gross profit of the Group decreased by 8.1% from RMB57.9 million for the six months ended June 30, 2024 to RMB53.2 million for the six months ended June 30, 2025. Gross profit margin is calculated as gross profit divided by revenue. The overall gross profit margin of the Group increased from 46.4% for the six months ended June 30, 2024 to 52.5% for the six months ended June 30, 2025, primarily due to: (i) the Group implemented process optimization and material price control to reduce costs; and (ii) the Group reduced some relatively unprofitable projects to improve overall profitability.

### Other Net Income

Our other net income decreased by 40.9% from RMB25.2 million for the six months ended June 30, 2024 to RMB14.9 million for the six months ended June 30, 2025, primarily due to (i) the decrease in exchange gains from exchange rate fluctuations; and (ii) the decrease in interest income from bank deposits.

**Selling and Distribution Costs**

Our selling and distribution expenses increased by 4.3% from RMB50.7 million for the six months ended June 30, 2024 to RMB52.9 million for the six months ended June 30, 2025, primarily due to the increase in our marketing activities by building a sales network covering major customer markets through the establishment of three major international sales regions covering Europe, the Middle East and Africa (EMEA), Asia Pacific (APAC) and North America, and promotional efforts for various new products.

**Administrative Expenses**

Our administrative expenses decreased by 7.7% from RMB80.4 million for the six months ended June 30, 2024 to RMB74.2 million for the six months ended June 30, 2025, primarily due to the Group's effective resource integration to reduce administrative expenses through optimization of management structure and collaboration domestically and internationally.

**R&D Expenses**

The following table sets forth the components of our research and development expenses for the period indicated.

| | **Six months ended June 30,** | |
|---|---|---|
| | **2025** | 2024 |
| | ***RMB'000*** | *RMB'000* |
| | **(unaudited)** | (unaudited) |
| Staff costs | **27,276** | 34,077 |
| Clinical trial expenses | **22,768** | 19,603 |
| Consumables expenses | **3,330** | 8,381 |
| Depreciation expenses | **2,956** | 3,728 |
| Others | **482** | 3,850 |
| **Total** | **56,812** | 69,639 |

Our research and development expenses decreased by 18.4% from RMB69.6 million for the six months ended June 30, 2024 to RMB56.8 million for the six months ended June 30, 2025, primarily due to that we have obtained the registration certificates for certain products and realized commercialization.

**Finance Costs**

Our financial costs consist of (i) interest on interest-bearing bank loans, and (ii) interest on lease liabilities. We recorded financial costs of RMB3.7 million and RMB7.2 for the six months ended June 30, 2024 and June 30, 2025, respectively. The increase was primarily attributable to the increase in the principal amount of bank borrowings.

**Income Tax**

We recorded income tax credit of RMB1.4 million and RMB1.5 million for the six months ended June 30, 2024 and 2025, respectively, the changes of which were resulted from changes in deferred tax assets and liabilities.

**Inventories**

Our inventories primarily consist of raw materials, finished goods and devices and instruments. We generally purchase raw materials for our in-house products based on the orders received. We maintain various types of testing kits, testing and cryostorage devices, and instruments embryo culture devices and embryo culture media and consumables.

Our inventories increased by 34.4% from RMB92.4 million as of December 31, 2024 to RMB124.2 million as of June 30, 2025, primarily due to the increase in inventory levels of products and raw materials in anticipation of rising demand.

**Trade and Other Receivables**

Our trade and other receivables decreased by 3.2% from RMB200.3 million as of December 31, 2024 to RMB193.9 million as of June 30, 2025, primarily due to the strengthened collection management and the improvement of customer payment efficiency.

**Foreign Exchange Risk**

Our financial statements are expressed in RMB, but certain of our cash and cash equivalents are denominated in foreign currencies, and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

**Trade and Other Payables**

Our trade and other payables decreased by 2.1% from RMB163.9 million as of December 31, 2024 to RMB160.5 million as of June 30, 2025, primarily due to the settlement of payable for our headquarters construction project.

## Financial Resources, Liquidity and Capital Structure

During the Reporting Period, we primarily funded our working capital requirements from bank loans, equity financing and cash generated from our operations. We monitor our uses of cash and cash flows on a regular basis and strive to maintain an optimum liquidity that can meet our working capital needs.

Our current assets decreased by 11.7% from RMB979.2 million as of December 31, 2024 to RMB865.0 million as of June 30, 2025, primarily due to the expansion of the Group's business operations and the settlement of the construction cost payable for our headquarters.

As of June 30, 2025, we had unsecured bank loans of RMB117.0 million with a floating interest rate of 3.1% per annum (as determined by LPR). As of the same date, we had secured bank loans of RMB219.0 million with an interest rate of 3.30%-3.65% per annum, which is determined based on LPR. The secured bank loans were pledged by the Group's land use right and certain property, plant and equipment. Our unsecured and secured bank loans were all denominated in RMB.

During the Reporting Period, we did not have any financial instruments for hedging purposes.

Due to the Global Offering, we received net proceeds of approximately HK$1,898.7 million (after deduction of underwriting fees, commissions and relevant expenses). We intend to apply such net proceeds in accordance with the purposes as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus and further revised and disclosed in the circulars of the Company dated November 16, 2021 and April 7, 2022 under the sections headed "Ordinary Resolution — Proposed Change in Use of Proceeds".

We follow a set of funding and treasury policies to manage our capital resources and mitigate potential risks. We endeavor to maintain an adequate level of cash and cash equivalents to address short-term funding needs. The Board would also consider various funding sources depending on our funding needs to ensure that the financial resources have been used in the most cost-effective and efficient way to meet our financial obligations. The Board reviews and evaluates our funding and treasury policy from time to time to ensure its adequacy and effectiveness.

## Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, we did not have any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures.

## Future Plans for Material Investments or Capital Assets

Save as disclosed in the sections headed — "Capital Commitments" and "Use of Proceeds from the Global Offering" in this announcement, the Group had no material capital expenditure plan nor other plans for material investments or capital assets as of the date of this announcement.

## Contingent Liabilities

As of June 30, 2025, we did not have any contingent liabilities.

## Capital Commitments

Capital commitments outstanding as of June 30, 2025 and December 31, 2024 not provided for in the consolidation financial statements were as follows:

| | **As of June 30, 2025** | As of December 31, 2024 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Authorised and contracted for | | |
| — Property, plants, and equipment | **12,488** | 56,327 |
| — Subscription of limited partnership interest in the fund | **2,500** | 5,205 |
| **Total** | **14,988** | 61,532 |

## Charge on Assets

Save for the secured bank loans of RMB219.0 million pledged by the Group's land use right, there was no charge on assets of the Group as of June 30, 2025.

## Gearing Ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of June 30, 2025, the Company was in a net cash position and thus, gearing ratio is not applicable.

## Employees and Remuneration

As of June 30, 2025, the Group had 419 employees (as of June 30, 2024: 528). The number of employees employed by the Group varies depending on our business requirement. The remuneration package of our employees includes salary, bonus and equity-settled share-based payment, which are generally determined by their qualifications, industry experience, position and performance. The Group makes contributions to social insurance and housing provident funds for its employees in Mainland China as required by the PRC laws and regulations, and makes contributions to relevant employee benefits for employees outside Mainland China as required by the relevant requirements of other regions in the PRC and other countries.

The total remuneration cost incurred by the Group for the six months ended June 30, 2025 was approximately RMB82.8 million, as compared to RMB92.3 million for the six months ended June 30, 2024. The decrease was primarily attributable to the integration of our global business operations and the optimization and downsizing of our employees.

During the six months ended June 30, 2025, the Group did not experience any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or results of operations, or any difficulty in recruiting employees.

The remuneration of the Directors, Supervisors and senior management is determined by the Board with reference to recommendations by the Remuneration and Appraisal Committee in respect of the overall remuneration policy and structure of the Directors, Supervisors and senior management of the Company (including but not limited to the performance appraisal criteria, procedures and key appraisal system, and major incentive plans, etc.) and based on the major scope, responsibility and importance of the respective positions of the Directors, Supervisors and senior management and the remuneration of the same position paid by comparable companies.

We recruit our personnel primarily through different methods, such as recruiting websites, recruiters and job fairs. All of our new employees are required to attend orientation and training programs so as to enable them to better understand our corporate culture, structure and policies, learn relevant laws and regulations, and raise their compliance awareness.

The employees of the Group based in Mainland China are required to participate in a central pension scheme operated by the local municipal government. The subsidiaries operating in Mainland China are required to contribute a certain percentage of their payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme. No forfeited contributions are available to reduce the contribution payable in the future years.

The employees of the Group's Australian subsidiaries are members of a state-managed retirement scheme in Australia. The Group's Australian subsidiaries are required to contribute a certain percentage of staff payroll costs to the retirement scheme to fund the benefits, which is the only obligation of the Group with respect to the retirement benefit scheme.

## OTHER INFORMATION

### Corporate Governance Practices

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and enhance its corporate value. The Company has adopted the CG Code as its own code of corporate governance since the Listing Date. The Company has complied with all applicable code provisions as set out in the CG Code for the six months ended June 30, 2025, except for a deviation from the code provision C.2.1 of part 2 of the CG Code, the roles of chairman of the Board and general manager of the Company are not separate and are both performed by Dr. Liang.

The Board believes that vesting the roles of both chairman of the Board and general manager of the Company in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the general manager of the Company at a time when it is appropriate by taking into account the circumstances of the Group as a whole.

To comply with the revised CG Code requiring gender diversity on the Nomination Committee as from July 1, 2025, the Company has appointed a female, namely Ms. JIANG Junchao (姜雋超) ("**Ms. Jiang**"), an executive Director and Dr. YEUNG Shu Biu William (楊樹標) ("**Dr. Yeung**"), an independent non-executive Director as members of the Nomination Committee, which was effective from June 25, 2025. As at the date of this announcement, the Nomination Committee currently consists of five members, namely Dr. LIANG Bo (梁波) (chairman), Dr. KANG Xixiong (康熙雄), Mr. LAM Siu Wing (林兆榮), Ms. Jiang and Dr. Yeung.

### Use of Proceeds from the Global Offering

The net proceeds received by the Company from its initial Global Offering (including the partial exercise of the over-allotment option) amounted to HK$1,898.7 million (equivalent to RMB1,584.1 million) (after deducting the underwriting commissions and relevant expenses).

The table below sets out the planned applications of the net proceeds:

| **Use of Proceeds** | **Planned applications** *HK$ in million* | **Percentage of total Proceeds** | **Actual amount of proceeds utilized as of January 1, 2025** *HK$ in million* | **Actual amount of proceeds unutilized as of June 30, 2025** *HK$ in million* | **Actual amount of proceeds utilized as of June 30, 2025** *HK$ in million* | **Percentage of proceeds from the Global Offering expected to be used in 2025** | **Expected timeframe for fully utilization of net proceeds** |
|---|---|---|---|---|---|---|---|
| **Core Product — PGT-A kit** | **379.7** | **20%** | **304.2** | **59.6** | **320.1** | **4.0%** | **Within the next one to two years** |
| Ongoing sales and marketing activities of our PGT-A kit and planned commercialization in China, in order to expand our sales channels, continue market coverage expansion, conduct patient education and clinical knowledge of physicians and increase the penetration rate of our PGT-A kit | 151.9 | 8% | 130.0 | 6.5 | 145.4 | 1.2% | |
| Optimizing the production process of our PGT-A kit by upgrading our existing manufacturing machinery and equipment, as well as procuring and installing new automated operational equipment and instruments to increase our production efficiency for PGT-A kit, and optimizing and upgrading our and PGT-A kits | 227.8 | 12% | 174.2 | 53.1 | 174.7 | 2.8% | |
| **Clinical trial, registration filing and commercialization of PGT-M kit** | **189.9** | **10%** | **142.8** | **23.5** | **166.4** | **2.5%** | **Within the next one to two years** |
| Clinical trial and registration filing of our PGT-M kit (including the relevant labor and consumables costs) | 132.9 | 7% | 114.7 | 17.2 | 115.7 | 1.0% | |
| Commercialization, sales and marketing activities of our PGT-M kit | 57.0 | 3% | 28.1 | 6.3 | 50.7 | 1.5% | |

| Use of Proceeds | Planned applications *HK$ in million* | Percentage of total Proceeds | Actual amount of proceeds utilized as of January 1, 2025 *HK$ in million* | Actual amount of proceeds unutilized as of June 30, 2025 *HK$ in million* | Actual amount of proceeds utilized as of June 30, 2025 *HK$ in million* | Percentage of proceeds from the Global Offering expected to be used in 2025 | Expected timeframe for fully utilization of net proceeds |
|---|---|---|---|---|---|---|---|
| **Development, clinical trials, registration filings and commercialization of our other products** | **569.6** | **30%** | **522.5** | **37.3** | **532.3** | **2.5%** | **Within the next one to two years** |
| Development, clinical trials, registration filings and commercialization of our other genetic test kit products | 227.8 | 12% | 225.0 | 1.9 | 225.9 | 0.2% | |
| Research, development, manufacturing and commercialization of our genetic testing devices and instruments | 341.8 | 18% | 297.5 | 35.4 | 306.4 | 2.3% | |
| **Improving our R&D capabilities and enhancing our technologies, including (i) introducing and acquiring new technologies in businesses upstream and downstream of genetic testing, to expand our product portfolio; (ii) recruiting talent in genetic testing, particularly senior R&D personnel with a high level of influence in the industry and with extensive international R&D and product development experience; (iii) funding our collaborations with academic and research institutions on joint research projects** | **284.8** | **15%** | **254.1** | **15.0** | **269.8** | **1.6%** | **Within the next one to two years** |
| **Constructing and decorating of our R&D center and expanding the manufacturing plant for our test kit products, testing devices and instruments** | **189.9** | **10%** | **96.0** | **87.5** | **102.4** | **4.9%** | **Within the next one to two years** |
| **Working capital and general corporate purposes** | **284.8** | **15%** | **280.9** | **2.6** | **282.2** | **0.2%** | **Within the next one to two years** |
| **Total** | **1,898.7** | **100%** | **1,600.5** | **225.5** | **1,673.2** | **15.7%** | |

The expected timeline for utilizing the net proceeds from the Global Offering is based on the best estimation of future market conditions made by the Company and subject to changes in accordance with our actual business operation. The net proceeds have applied in the manner as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus and further revised and disclosed in the circulars of the Company dated November 16, 2021 and April 7, 2022 under the sections headed "Ordinary Resolution — Proposed Change in Use of Proceeds".

**Directors' and Supervisors' securities Transactions**

The Company has adopted the Model Code as its own code of conduct regarding Directors' and Supervisors' securities transactions since the Listing Date. Having made specific enquiry of all Directors and Supervisors, each of the Directors and Supervisors has confirmed that he/she has complied with the Model Code during the Reporting Period.

The Company's employees, who are likely to be in possession of inside information of the Company, have also been subject to the Model Code. No incident of non-compliance of the Model Code was noted by the Company during the Reporting Period.

**Company's Compliance with relevant Laws and Regulations**

During the Reporting Period and up to the date of this announcement, the Group had complied with the laws, regulations and regulatory requirements of the places where the Group operates in all material respects, including the requirements under the Companies Ordinance, the Listing Rules, the SFO and the CG Code for, among other things, the disclosure of information and corporate governance. During the Reporting Period and up to the date of this announcement, none of the Group and the Directors, Supervisors and senior management of the Company were subject to any investigation initiated or administrative penalties imposed by the CSRC, banned from entering the market, identified as inappropriate candidates, publicly condemned by stock exchanges, subject to mandatory measures, transferred to judicial organs or held criminally responsible, and none were involved in any other litigation, arbitration or administrative proceedings which would have a material adverse impact on our business, financial condition or results of operations.

**Interim Dividends**

The Directors do not recommend the payment of an interim dividend for the Reporting Period (2024 interim dividend: nil).

## Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including any sale or transfer of treasury shares (as defined in the Listing Rules)) during the Reporting Period (six months ended June 30, 2024: nil).

As at June 30, 2025, the Company did not hold any shares as treasury shares.

## Review of Interim Results by the Audit Committee

The Audit Committee consists of two independent non-executive Directors and one non-executive Director, namely Mr. LAM Siu Wing, Dr. KANG Xixiong and Mr. WANG Weipeng. Mr. LAM Siu Wing, being the chairman of the Audit Committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Company and overseeing the audit process.

The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Company and the interim results for the six months ended June 30, 2025.

KPMG, the Group's external auditor, has carried out a review of the unaudited interim consolidated financial statements for the six months ended June 30, 2025 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the HKICPA.

## Publication of Interim Results and Interim Report

This interim results announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.basecare.cn). The interim report for the six months ended June 30, 2025 containing all the information in accordance with the requirements under the Listing Rules will be despatched (if requested) to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

## APPRECIATION

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By Order of the Board
**Suzhou Basecare Medical Corporation Limited**
**Dr. Liang Bo**
*Chairman and General Manager*

Suzhou, PRC, August 29, 2025

*As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye, Mr. WANG Weipeng and Mr. LING Yang as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.*

| | |
|---|---|
| "AI" | artificial intelligence |
| "associate(s)" | has the meaning ascribed to it under the Listing Rules |
| "Audit Committee" | the audit committee of the Board |
| "Basecare Investment" | Suzhou Basecare Investment Management Enterprise (Limited Partnership) (蘇州貝康投資管理企業(有限合夥)), a limited partnership established on May 23, 2016, through which, certain former employees, employees and advisors of our Group were indirectly beneficially interested in approximately 13.19% of the equity interests in our Company as of the date of this announcement. Basecare Investment is one of our Controlling Shareholders |
| "BMX" | BMX Holdco Pte. Ltd., a company incorporated in Singapore and a wholly owned subsidiary as of the date of this announcement |
| "BMX Acquisition" | the acquisition of BMX and its seven subsidiaries by the Company, which was completed on June 21, 2023 |
| "Board" | the board of directors of the Company |
| "CE" | European conformity (conformité européenne) |
| "CG Code" | the Corporate Governance Code as set out in Appendix C1 to the Listing Rules |
| "China" or "the PRC" | the People's Republic of China excluding, for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, Hong Kong, Macau Special Administrative Region and Taiwan |
| "Company" | Suzhou Basecare Medical Corporation Limited (蘇州貝康醫療股份有限公司) |
| "Controlling Shareholder(s)" | has the meaning ascribed thereto under the Listing Rules and unless the context requires otherwise, refers to Dr. Liang and/or Basecare Investment |

| | |
|---|---|
| "Core Product(s)" | has the meaning ascribed to it in Chapter 18A of the Listing Rules; for purposes of this announcement, our Core Product refers to our PGT-A kit |
| "CSRC" | the China Securities Regulatory Commission |
| "Director(s)" | the director(s) of our Company, including all executive directors, non-executive directors and independent non-executive directors |
| "Domestic Shares" | ordinary shares in the share capital of our Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi by domestic investors |
| "Dr. Liang" | Dr. LIANG Bo (梁波), our founder, executive Director, chairman of the Board, general manager and Controlling Shareholder |
| "FDA" | The United States Food and Drug Administration |
| "Genea Biomedx" | Genea Biomedx Pty Ltd., a wholly owned subsidiary of BMX |
| "Global Offering" | the offer of H Shares for subscription as described in the Prospectus |
| "GMP" | Good Manufacturing Practice, guidelines and regulations from time to time issued pursuant to the PRC Drug Administration Law (《中華人民共和國藥品管理法》) as part of quality assurance which aims to minimize the risks of contamination, cross contamination, confusion and errors during the manufacture process of pharmaceutical products and to ensure that pharmaceutical products subject to these guidelines and regulations are consistently produced and controlled in conformity to quality and standards appropriate for their intended use |
| "Group", "we" or "us" | the Company and its subsidiaries |
| "H Shares" | overseas listed shares in the share capital of our Company with a nominal value of RMB1.00 each, which are subscribed for and traded in HK dollars |

| | |
|---|---|
| "HK$" | Hong Kong dollars, the lawful currency of Hong Kong |
| "Hong Kong" | the Hong Kong Special Administrative Region of the PRC |
| "iARMS" | intelligent assisted reproduction management system |
| "IFRS" | International Financial Reporting Standards |
| "IVF" | in vitro fertilization, a process where the egg and sperm are incubated together to a fertilized embryo in an in vitro system to achieve pregnancy |
| "IVM" | in vitro maturation |
| "Jiangsu MPA" | Jiangsu Medical Products Administration |
| "Listing" | the listing of our H Shares on the Main Board of the Stock Exchange |
| "Listing Date" | February 8, 2021, being the date on which dealings in our H Shares first commenced on the Main Board of the Stock Exchange |
| "Listing Rules" | the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time |
| "LPR" | Loan Prime Rate |
| "Main Board" | the Main Board of the Stock Exchange |
| "Model Code" | the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules |
| "NMPA" | the National Medical Products Administration of China (國家藥品監督管理局) or, where the context so requires, its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局), or CFDA |
| "Nomination Committee" | the nomination committee of the Board |
| "PCR" | polymerase chain reaction, a method used to amplify copies of specific DNA sequences rapidly |

| | |
|---|---|
| "PGT" | pre-implantation genetic testing, a test performed before the implantation of an embryo to screen and diagnose the DNA from embryos for determining genetic abnormalities. These include PGT for aneuploidy (PGT-A), PGT for monogenic defects (PGT-M) and PGT for chromosomal rearrangements (PGT-SR) |
| "Prospectus" | the prospectus in relation to the Global Offering issued by the Company dated January 27, 2021 |
| "R&D" | research and development |
| "Remuneration and Appraisal Committee" | the remuneration and appraisal committee of the Board |
| "Renminbi" or "RMB" | Renminbi Yuan, the lawful currency of China |
| "Reporting Period" | the six months ended June 30, 2025 |
| "SFO" | Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time |
| "Share(s)" | shares in the share capital of our Company, with a nominal value of RMB1.00 each, comprising Domestic Share(s), H Share(s) and Unlisted Foreign Share(s) |
| "Shareholder(s)" | holder(s) of Shares |
| "sq.m." | square meter(s) |
| "Stock Exchange" | The Stock Exchange of Hong Kong Limited |
| "Supervisor(s)" | the supervisor(s) of the Company |
| "TGA" | The Therapeutic Goods Administration of Australia |
| "Unlisted Foreign Shares" | unlisted ordinary Share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for in a currency other than RMB |
| "%" | per cent |